<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Laucyte-Cibulskiene A</submitter><funding>hjärt-lungfonden</funding><funding>Austrian Science Fund FWF</funding><funding>canadian institutes of health research</funding><funding>njurfonden</funding><funding>scientific independence of young researcher program of the italian ministry of university</funding><funding>novo nordisk postdoctoral fellowship</funding><funding>“la caixa” foundation</funding><funding>vetenskapsrådet</funding><funding>Karolinska Institute</funding><pagination>50</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8444580</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Sex differences are underappreciated in the current understanding of cardiovascular disease (CVD) in association with chronic kidney disease (CKD). A hallmark of CKD is vascular aging that is characterised, amongst others, by; systemic inflammation, microbiota disbalance, oxidative stress, and vascular calcification-features linked to atherosclerosis/arteriosclerosis development. Thus, it is the necessary to introduce novel biomarkers related to athero-/arteriosclerotic damage for better assessment of vascular ageing in patients CKD. However, little is known about the relationship between uraemia and novel CVD biomarkers, such as growth differentiation factor-15 (GDF-15), cartilage glycoprotein-39 (YKL-40) and matrix metalloproteinase-9 (MMP-9). Therefore, we hypothesise that there are sex-specific relationships between GDF-15, YKL-40, MMP-9 levels in end-stage kidney disease (ESKD) patients in relation to gut microbiota, vascular calcification, inflammation, comorbidities, and all-cause mortality.&lt;h4>Methods&lt;/h4>ESKD patients, males (n = 151) and females (n = 79), not receiving renal replacement therapy were selected from two ongoing prospective ESKD cohorts. GDF-15, YKL-40 and MMP9 were analysed using enzyme-linked immunosorbent assay kits. Biomarker levels were analysed in the context of gut microbiota-derived trimethylamine N-oxide (TMAO), vascular calcification, inflammatory response, oxidative stress, comorbidities, and all-cause mortality.&lt;h4>Results&lt;/h4>Increased GDF-15 correlated with higher TMAO in females only, and with higher coronary artery calcification and IL-6. In females, diabetes was associated with elevated GDF-15 and MMP-9, whilst males with diabetes only had elevated GDF-15. No associations were found between biomarkers and CVD comorbidity. Deceased males and females had higher GDF-15 concentrations (p = 0.01 and p &lt; 0.001, respectively), meanwhile only YKL-40 was increased in deceased males (p = 0.02).&lt;h4>Conclusions&lt;/h4>In conclusion, in males GDF-15 and YKL-40 were related to vascular calcification, inflammation, and oxidative stress, whilst in females GDF-15 was related to TMAO. Increased levels of YKL-40 and GDF-15 in males, and only GDF-15 in females, were associated with all-cause mortality. Our findings suggest that sex-specific associations of novel CVD biomarkers have a potential to affect development of cardiovascular complications in patients with ESKD.</pubmed_abstract><journal>Biology of sex differences</journal><pubmed_title>Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality.</pubmed_title><pmcid>PMC8444580</pmcid><funding_grant_id>20160384</funding_grant_id><funding_grant_id>RBSI14HNVT</funding_grant_id><funding_grant_id>I 4209</funding_grant_id><funding_grant_id>FWF</funding_grant_id><funding_grant_id>2018-00932</funding_grant_id><funding_grant_id>100010434</funding_grant_id><funding_grant_id>GNP161904</funding_grant_id><funding_grant_id>I4209</funding_grant_id><pubmed_authors>Kautzky-Willer A</pubmed_authors><pubmed_authors>GOING-FWD Consortium</pubmed_authors><pubmed_authors>Herrero MT</pubmed_authors><pubmed_authors>Ripsweden J</pubmed_authors><pubmed_authors>Soderberg M</pubmed_authors><pubmed_authors>Stenvinkel P</pubmed_authors><pubmed_authors>Laucyte-Cibulskiene A</pubmed_authors><pubmed_authors>Raparelli V</pubmed_authors><pubmed_authors>Kublickiene K</pubmed_authors><pubmed_authors>Ebert T</pubmed_authors><pubmed_authors>Pilote L</pubmed_authors><pubmed_authors>Tosti G</pubmed_authors><pubmed_authors>Hernandez L</pubmed_authors><pubmed_authors>Brismar TB</pubmed_authors><pubmed_authors>Norris CM</pubmed_authors><pubmed_authors>Ward LJ</pubmed_authors><pubmed_authors>Tucci C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality.</name><description>&lt;h4>Background&lt;/h4>Sex differences are underappreciated in the current understanding of cardiovascular disease (CVD) in association with chronic kidney disease (CKD). A hallmark of CKD is vascular aging that is characterised, amongst others, by; systemic inflammation, microbiota disbalance, oxidative stress, and vascular calcification-features linked to atherosclerosis/arteriosclerosis development. Thus, it is the necessary to introduce novel biomarkers related to athero-/arteriosclerotic damage for better assessment of vascular ageing in patients CKD. However, little is known about the relationship between uraemia and novel CVD biomarkers, such as growth differentiation factor-15 (GDF-15), cartilage glycoprotein-39 (YKL-40) and matrix metalloproteinase-9 (MMP-9). Therefore, we hypothesise that there are sex-specific relationships between GDF-15, YKL-40, MMP-9 levels in end-stage kidney disease (ESKD) patients in relation to gut microbiota, vascular calcification, inflammation, comorbidities, and all-cause mortality.&lt;h4>Methods&lt;/h4>ESKD patients, males (n = 151) and females (n = 79), not receiving renal replacement therapy were selected from two ongoing prospective ESKD cohorts. GDF-15, YKL-40 and MMP9 were analysed using enzyme-linked immunosorbent assay kits. Biomarker levels were analysed in the context of gut microbiota-derived trimethylamine N-oxide (TMAO), vascular calcification, inflammatory response, oxidative stress, comorbidities, and all-cause mortality.&lt;h4>Results&lt;/h4>Increased GDF-15 correlated with higher TMAO in females only, and with higher coronary artery calcification and IL-6. In females, diabetes was associated with elevated GDF-15 and MMP-9, whilst males with diabetes only had elevated GDF-15. No associations were found between biomarkers and CVD comorbidity. Deceased males and females had higher GDF-15 concentrations (p = 0.01 and p &lt; 0.001, respectively), meanwhile only YKL-40 was increased in deceased males (p = 0.02).&lt;h4>Conclusions&lt;/h4>In conclusion, in males GDF-15 and YKL-40 were related to vascular calcification, inflammation, and oxidative stress, whilst in females GDF-15 was related to TMAO. Increased levels of YKL-40 and GDF-15 in males, and only GDF-15 in females, were associated with all-cause mortality. Our findings suggest that sex-specific associations of novel CVD biomarkers have a potential to affect development of cardiovascular complications in patients with ESKD.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Sep</publication><modification>2025-04-26T02:54:26.669Z</modification><creation>2022-02-11T11:04:01.31Z</creation></dates><accession>S-EPMC8444580</accession><cross_references><pubmed>34526107</pubmed><doi>10.1186/s13293-021-00393-0</doi></cross_references></HashMap>